The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Open accessAbstract
RationaleThis dose-effect study extends previous observations showing that psilocybin can occasion mystical-type experiences having persisting positive effects on attitudes, mood, and behavior.ObjectivesThis double-blind study evaluated psilocybin (0, 5, 10, 20, 30 mg/70 kg, p.o.) administered under supportive conditions.MethodsParticipants were 18 adults (17 hallucinogen-naïve). Five 8-h sessions were conducted individually for each participant at 1-month intervals. Participants were randomized to receive the four active doses in either ascending or descending order (nine participants each). Placebo was scheduled quasi-randomly. During sessions, volunteers used eyeshades and were instructed to direct their attention inward. Volunteers completed questionnaires assessing effects immediately after and 1 month after each session, and at 14 months follow-up.ResultsPsilocybin produced acute perceptual and subjective effects including, at 20 and/or 30 mg/70 kg, extreme anxiety/fear (39% of volunteers) and/or mystical-type experience (72% of volunteers). One month after sessions at the two highest doses, volunteers rated the psilocybin experience as having substantial personal and spiritual significance, and attributed to the experience sustained positive changes in attitudes, mood, and behavior, with the ascending dose sequence showing greater positive effects. At 14 months, ratings were undiminished and were consistent with changes rated by community observers. Both the acute and persisting effects of psilocybin were generally a monotonically increasing function of dose, with the lowest dose showing significant effects.ConclusionsUnder supportive conditions, 20 and 30 mg/70 kg psilocybin occasioned mystical-type experiences having persisting positive effects on attitudes, mood, and behavior. Implications for therapeutic trials are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“High MEQ-30 scores have also been found to predict changes in personality-trait openness (MacLean et al., 2012) and positive changes in attitudes, mood, and behavior (Griffiths et al., 2011).”
From Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics (2024) · cites this paper as Griffiths et al., 2011
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“it has been repeatedly found that psychedelic-induced mystical-type experiences and ego dissolution, the latter a phenomenon characterized by the reduction in self-referential awareness, disruption self-world boundaries, and increased feelings of unity with one’s surroundings (55), correlates with long-term (positive) outcomes (23, 52–54, 56–58).”
From Decreases in State and Trait Anxiety Post-psilocybin: A Naturalistic, Observational Study Among Retreat Attendees (2022) · cites this paper as [57]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Compared to the active placebo group, both groups which received a high dose of psilocybin reported significantly higher enhancements in mood, well-being and life satisfaction, as assessed by the Persisting Effects Questionnaire (87).”
From Examining the Potential Synergistic Effects Between Mindfulness Training and Psychedelic-Assisted Therapy (2021) · cites this paper as [87]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“phase I and II studies suggest a dose-dependent effect on the quality of the psychedelic experience [54, 76]”
The cited source says what the claim attributes to it.
In the citing paper
“5 mg of psilocybin was shown to induce subjective changes significantly greater than those of an inert placebo; [76]”
The cited source says what the claim attributes to it.
In the citing paper
“with high mystical experience scores associated with 30 mg/70 kg of psilocybin [76]”
The cited source says what the claim attributes to it.
In the citing paper
“Undergoing a mystical-type experience during the acute effects of a psychedelic has been associated with healthy volunteers reporting an improvement in their wellbeing [51, 52], and reductions in depression symptoms in participants with life-threatening cancer [19, 20].”
From The psychological processes of classic psychedelics in the treatment of depression: a systematic review protocol (2022) · cites this paper as [51]
The cited source says what the claim attributes to it.
In the citing paper
“Mindfulness meditation and mindfulness-based interventions can augment positive affect in healthy and clinical populations acutely and long-term (10, 88) and a similar mood-enhancing potential has been demonstrated for psychedelics such as psilocybin (29, 38, 60, 83, 87).”
From Examining the Potential Synergistic Effects Between Mindfulness Training and Psychedelic-Assisted Therapy (2021) · cites this paper as [87]
The cited source says what the claim attributes to it.
In the citing paper
“Controlled studies where subjects achieved mystical experiences under the effects of psilocybin showed personal long-term benefits (Griffiths et al., 2008; Griffiths et al., 2011).”
From Psychological variables implied in the therapeutic effect of ayahuasca: A contextual approach (2018) · cites this paper as Griffiths et al., 2011
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Importantly, previous studies utilising psychedelic-administration outside of a mindfulness-enhancing context have failed to show such positive trait changes (83, 87, 133), with the exception of trait openness (74, 134).”
From Examining the Potential Synergistic Effects Between Mindfulness Training and Psychedelic-Assisted Therapy (2021) · cites this paper as [87]
Experimental — accuracy not yet measuredIn the citing paper
“and a dose-response study in healthy volunteers suggested that optimum psilocybin dosing for eliciting a well-tolerated yet transcendent experience may be between 0·29 mg/kg and 0·43 mg/kg [32].”
From Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: an open-label safety and feasibility pilot study. (2020) · cites this paper as [32]
In the citing paper
“Self-reported increases in interpersonal closeness and positive/altruistic social effects were reported 1, 2, 6, and 14 months after one and two administrations of psilocybin (89–92).”
From Modulation of Social Cognition via Hallucinogens and “Entactogens” (2019) · cites this paper as [91]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 23×
“The questionnaire included three additional questions (see Griffiths et al. 2006 for more specific wording): (1) How personally meaningful was the experience?”
BackgroundMethodResultInfluentialSelf-citationThe Psychology of Religion: An Empirical Approach
Donahue, M. J., Hood, R. W., Spilka, B., Hunsberger, B. E., & Gorsuch, R. L. (1998) · Journal for the Scientific Study of Religion · doi:10.2307/1388044 · Cited by 1,339
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206
Human hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203
Self-citationMartin, W. R., Sloan, J. W., SAPIRA, J. D., & Jasinski, D. R. (1971) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1971122part1245 · Cited by 945
The Psychology of Religion: An Empirical Approach
Hall, C. M., Spilka, B., Hood, R. W., & Gorsuch, R. L. (1986) · Journal for the Scientific Study of Religion · doi:10.2307/1386305 · Cited by 943
Griffiths, R., Richards, W., Johnson, M., McCann, U., & Jesse, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108094300 · Cited by 905
Self-citationEvidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents
Glennon, R. A., Titeler, M., & MCKENNEY, J. D. J. (1984) · Life Sciences · doi:10.1016/0024-3205(84)90436-3 · Cited by 635
The Psychology of Religion: An Empirical Approach
Hunsberger, B. E., Spilka, B., Hood, R. W., & Gorsuch, R. L. (1986) · Review of Religious Research · doi:10.2307/3511875 · Cited by 626
Research works printed but not linked: 5
- Metzner R (2004) Teonanacatl: sacred mushroom of visions. Four Tree, El Verano
- Metzner R, Litwin G, Weil G (1965) The relation of expectation and mood to psilocybin reactions: a questionnaire study. Psychedelic Rev 5:3–39
- Pahnke W (1963) Drugs and mysticism: an analysis of the relationship between psychedelic drugs and the mystical consciousness. Thesis presented to the President and Fellows of Harvard University for the Ph.D. in Religion and Society
- Stolaroff MJ (1997) The secret chief revealed. Multidisciplinary Association for Psychedelic Studies, Sarasota
- VandeCreek L (1999) The death transcendence scale. In: Hill PC, Hood RW Jr (eds) Measures of religiosity. Religious Education Press, Birmingham, pp 442–445
Cited by
Sorted by citations
Items 501–600 of 979
ENTHEOGENS, MYSTICISM, AND NEUROSCIENCE
Cole‐Turner, R. (2014) · Zygon® · doi:10.1111/zygo.12110 · Cited by 12
Psilocybin as a Novel Pharmacotherapy for Treatment-Refractory Anorexia Nervosa
Rodan, S.-C., Aouad, P., McGregor, I. S., & Maguire, S. (2021) · OBM Neurobiology · doi:10.21926/obm.neurobiol.2102102 · Cited by 12
Fagetti, A., & Mercadillo, R. E. (2022) · Anthropology of Consciousness · doi:10.1111/anoc.12163 · Cited by 12
The possible place for psychedelics in pharmacotherapy of mental disorders
Wojtas, A. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00550-9 · Cited by 12
Long-lasting analgesic effect of the psychedelic drug changa: A case report
Oña, G., & Troncoso, S. (2019) · Journal of Psychedelic Studies · doi:10.1556/2054.2019.001 · Cited by 12
Assessing potential of psilocybin for depressive disorders
Kozak, Z., Johnson, M. W., & Aaronson, S. T. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2273493 · Cited by 11
Self-citationPsychedelic Microdosing, Mindfulness, and Anxiety: A Cross-Sectional Mediation Study
Hartong, V., & van Emmerik, A. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2080616 · Cited by 11
“…in associated outcomes (Bohlmeijer et al. 2010; Eberth and Sedlmeier 2012; Hofmann et al. 2010), phenomenology (Berkovich-Ohana and Glicksohn 2017; Griffiths et al. 2011; Hanley, Nakamura, and Garland 2018; Liechti, Dolder, and Schmid 2017; Nour et al. 2016; Reavley and Pallant 2009; Russ and…”
BackgroundJohansen, L., Liknaitzky, P., Nedeljkovic, M., Mastin-Purcell, L., & Murray, G. (2022) · Systematic Reviews · doi:10.1186/s13643-022-01930-7 · Cited by 11
“Undergoing a mystical experience has been associated with positive wellbeing in healthy volunteers (43, 44), and reductions in depression symptoms in participants with life-threatening cancer (18, 45).”
BackgroundWoollacott, M. H., Riddle, J., Hermansson, N., Sacchet, M. D., & Ingram, D. M. (2024) · EXPLORE · doi:10.1016/j.explore.2024.103056 · Cited by 11
Stroud, J., Rice, C., Orsini, A., Schlosser, M., Lee, J., Mandy, W., & Kamboj, S. K. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06685-8 · Cited by 11
The therapeutic potential of psilocybin beyond psychedelia through shared mechanisms with ketamine
Park, D., Lee, G., Lee, W.-G., Kim, B. S., Lee, Y., & Kim, J. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03100-2 · Cited by 11
Mathai, D. S., Hilbert, S. N., Sepeda, N. D., Strickland, J. C., Griffiths, R. R., & Garcia‐Romeu, A. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2023.0035 · Cited by 11
Self-citationThe role of psychedelics in palliative care reconsidered: A case for psilocybin
Kelmendi, B., Corlett, P. R., Ranganathan, M., D’Souza, C., & Krystal, J. H. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675781 · Cited by 11
Shaw, L., Rea, K., Lachowsky, N. J., & Roth, E. A. (2022) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2054746 · Cited by 11
Muscat, S.-A., Hartelius, G., Crouch, C., & Morin, K. W. (2022) · Psych · doi:10.3390/psych4010012 · Cited by 11
Herrmann, Z. M., Levin, A. W., Cole, S. P., Slabaugh, S., Barnett, B. S., Penn, A., Jain, R., Raison, C. L., Rajanna, B., & Jain, S. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2023.0030 · Cited by 11
Johnstad, P. G. (2015) · Nordic Studies on Alcohol and Drugs · doi:10.1515/nsad-2015-0053 · Cited by 11
The factor structure of the Mystical Experience Questionnaire (MEQ): Reply to Bouso et al., 2016
Barrett, F. S., & Griffiths, R. R. (2017) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2564 · Cited by 11
Self-citationStenbæk, D. S., Kristiansen, S., Burmester, D., Madsen, M. K., Frokjaer, V. G., Knudsen, G. M., & Fisher, P. M. (2019) · Human Brain Mapping · doi:10.1002/hbm.24511 · Cited by 11
Developing a short form of the Awe Experience Scale (AWE-SF) in psychedelic samples
Graziosi, M., Rohde, J. S., Lake, S., Lucas, P., Kaufman, S. B., & Yaden, D. B. (2024) · PLoS ONE · doi:10.1371/journal.pone.0314469 · Cited by 10
Klučková, T., Nikolič, M., Tylš, F., Viktorin, V., Vejmola, Č., Viktorinová, M., Bravermanová, A., Androvičová, R., Andrashko, V., Korčák, J., et al. (2025) · Pharmacological Reports · doi:10.1007/s43440-025-00742-5 · Cited by 10
Brudner, R. M., Kaczmarek, E. S., Blainey, M. G., Schulz-Quach, C., Meshkat, S., Doyle, Z., Lipsitz, O., Offman, H., Sethi, R., Weiglein, G., et al. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251346697 · Cited by 10
5-HT2A and 5-HT2C receptors as potential targets for the treatment of nicotine use and dependence
Higgins, G. A., & Sellers, E. M. (2021) · Progress in brain research · doi:10.1016/bs.pbr.2021.01.007 · Cited by 10
Nicholas, C. R. N., Horton, D. M., Malicki, J., Baltes, A., Hutson, P. R., & Brown, R. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2023.0012 · Cited by 10
Psychothérapie assistée par psychédéliques (PAP) : le modèle genevois
Seragnoli, F., Thorens, G., Penzenstadler, L. E., Furtado, L., Buchard, A., Bachmann, S., Iuga, R., Khatcherian, E., Nowotarski, A., Sabé, M., et al. (2024) · Annales Médico-psychologiques revue psychiatrique · doi:10.1016/j.amp.2024.05.014 · Cited by 10
CCNP Innovations in Neuropsychopharmacology Award
Gobbi, G. (2024) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.240037 · Cited by 10
The chemical induction of synaesthesia
Luke, D. P., Lungu, L., Friday, R., & Terhune, D. B. (2022) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2832 · Cited by 10
Vargas-Pérez, H., Grieder, T. E., & van der Kooy, D. (2022) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2033889 · Cited by 10
Grob, C. S., Bossis, A. P., & Griffiths, R. R. (2022) · Springer eBooks · doi:10.1007/978-3-030-85702-8_5 · Cited by 10
Self-citationPsychedelic medicine at a crossroads: Advancing an integrative approach to research and practice
Gobbi, G., Inserra, A., Greenway, K. T., Lifshitz, M., & Kirmayer, L. J. (2022) · Transcultural Psychiatry · doi:10.1177/13634615221119388 · Cited by 10
Psychedelics and psychological strengths
Brasher, T. J., Rosen, D., & Spinella, M. (2023) · International Journal of Wellbeing · doi:10.5502/ijw.v13i1.2325 · Cited by 10
Bioenergy and its implication for yoga therapy
Narayanan, C., Korotkov, K. G., & Srinivasan, T. (2018) · International Journal of Yoga · doi:10.4103/ijoy.ijoy_54_17 · Cited by 10
Psychology of mysticism: Toward a layered hierarchy model
Chen, Z. J. (2024) · Archive for the Psychology of Religion · doi:10.1177/00846724241255129 · Cited by 9
Martin, D. A., Delgado, A. M., & Calu, D. J. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-024-01912-4 · Cited by 9
Butler, M., Bird, C., Maggio, C., Durden, A., Modlin, N. L., Campbell‐Coker, K., Edwards, M. J., Pick, S., Millman, L. S. M., Lowery, E., et al. (2024) · Wellcome Open Research · doi:10.12688/wellcomeopenres.22543.1 · Cited by 9
Healy, C. J., Frazier, A., Kirsch, S., Sanford, A., Garcia‐Romeu, A., Todman, M., Varon, J. P., & D'Andrea, W. M. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111361 · Cited by 9
Carvour, H. M., Radke, A. K., & French, N. S. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1587794 · Cited by 9
Bukovsky, D., Amaev, A., Song, J., Kyte, S., Carmona-Torres, E., Ueno, F., Luca, V. D., Strafella, A. P., Husain, M. I., Graff‐Guerrero, A., et al. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111541 · Cited by 9
Psilocybin: The most effective moral bio‐enhancer?
Rakić, V. (2023) · Bioethics · doi:10.1111/bioe.13196 · Cited by 9
Context is a Critical for Psychoactive Drug Effects
Greenway, K. T. (2023) · CNS Drugs · doi:10.1007/s40263-023-01053-0 · Cited by 9
Psychedelics in Psychiatry, the Nursing Influence, and the Future of Psychedelic Therapies
Spotswood, C. J. (2024) · Journal of the American Psychiatric Nurses Association · doi:10.1177/10783903231222930 · Cited by 9
Psychedelic Microdosing among Young Adults from Southern California
Harlow, A. F., Hendricks, P. S., Leventhal, A. M., & Barrington‐Trimis, J. L. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2313684 · Cited by 9
Hovmand, O. R., Madsen, M. K., Fisher, P. M., & Stenbæk, D. S. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241269669 · Cited by 9
Considering distinct positive emotions in psychedelic science
Goldy, S. P., Hendricks, P. S., Keltner, D. J., & Yaden, D. B. (2024) · International Review of Psychiatry · doi:10.1080/09540261.2024.2394221 · Cited by 9
Death Anxiety Among Users and Non-Users of Psychedelics
Garcia, A. C. M., Maia, L. O., Meireles, E., Nogueira, D. A., & Tófoli, L. F. (2025) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2025.2451035 · Cited by 9
Empirische Untersuchung veränderter Bewusstseinszustände
Schmidt, T. T., & Majić, T. (2017) · Springer eBooks · doi:10.1007/978-3-642-55125-3_65 · Cited by 9
APPLIED MYSTICISM: A DRUG‐ENABLED VISIONARY EXPERIENCE AGAINST MORAL BLINDNESS
Ballesteros, V. (2019) · Zygon® · doi:10.1111/zygo.12544 · Cited by 9
Anxiety and Affective Symptoms Related to the Use of Classic Psychedelics: A Systematic Review
Viljoen, G., & Betzler, F. (2024) · Current topics in behavioral neurosciences · doi:10.1007/7854_2024_534 · Cited by 8
Caraccio, M., Cheung, K., Mann, S. P., Bruce, L., Jacobs, E., Villiger, D., Sandbrink, J. D., Register, C., Hannikainen, I. R., Høeg, M. L., et al. (2025) · Philosophical Psychology · doi:10.1080/09515089.2025.2532761 · Cited by 8
Žuljević, M. F., Mijatović, A., Marušić, S. L., Kudrjavets, G., Buljan, I., & Hren, D. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2274382 · Cited by 8
EMBARK Psychedelic Therapy for Depression
Brennan, B., & Belser, A. (2024) · doi:10.1093/9780197762622.001.0001 · Cited by 8
Kajonius, P., Sjöström, D., & Claesdotter‐Knutsson, E. (2025) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2444892 · Cited by 8
View, meditation, action: A Tibetan framework to inform psychedelic-assisted therapy
Simonds, C. H. (2023) · Journal of Psychedelic Studies · doi:10.1556/2054.2023.00255 · Cited by 8
Psychological research of awe: Definition, functions, and application in psychotherapy
Luo, L., Mao, J., Chen, S., Gao, W., & Yuan, J. (2021) · Stress and Brain · doi:10.26599/sab.2020.9060003 · Cited by 8
Savoldi, R., Roazzi, A., & Sales, R. C. D. O. (2023) · International Journal for the Psychology of Religion · doi:10.1080/10508619.2023.2185369 · Cited by 8
Does the Nervous System Have an Intrinsic Archaic Language? Entoptic Images and Phosphenes
Sayin, H. U. (2014) · NeuroQuantology · doi:10.14704/nq.2014.12.3.756 · Cited by 8
Takiwasi: addiction treatment in the "Singing House"
O’Shaughnessy, D. M. (2017) · ResearchOnline at James Cook University (James Cook University) · doi:10.4225/28/5a9dce00eafa6 · Cited by 8
Mapping Psilocybin-Assisted Therapies: A Scoping ReviewPreprint
Shore, R., Ioudovski, P., Goldie, C. E., McKeown, S., & Dumont, É. C. (2019) · medRxiv · doi:10.1101/2019.12.04.19013896 · Cited by 8
Nondual Awareness: Consciousness-as-such as non-representational reflexivityPreprint
Josipovic, Z. (2018) · MindRxiv (OSF Preprints) · doi:10.31231/osf.io/jvup5 · Cited by 8
ACNP 61st Annual Meeting: Poster Abstracts P1 - P270
(2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01484-1 · Cited by 8
Breaking the chains of depression: A systematic review and meta-analysis of psilocybin therapy
Khan, F. A., Pandupuspitasari, N. S., Tencomnao, T., & Chuchawankul, S. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120882 · Cited by 7
Chen, Z. J. (2026) · Cambridge University Press eBooks · doi:10.1017/9781009420860 · Cited by 7
Perkins, D., Sarris, J. J., Cowley‐Court, T., Aicher, H., Tófoli, L. F., Bouso, J. C., Opaleye, E. S., Halman, A., Coelho, N. L. G., & Schubert, V. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2424288 · Cited by 7
Glynos, N. G., Baker, A., Aday, J. S., Kruger, D. J., Boehnke, K. F., Lake, S., & Lucas, P. (2025) · British Journal of Pain · doi:10.1177/20494637251319497 · Cited by 7
Millón, M. B. B., Noguera, L., Bruno, D., Vita, L., Zanino, M., Kassuha, D., Ortiz, J. E., Feresin, G. E., Díaz-Dellavalle, P., Orosco, L. L., et al. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02167-3 · Cited by 7
Wittenkeller, L. M., Gudelsky, G. A., Winhusen, T. M., & Amato, D. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70181 · Cited by 7
Psychedelic therapy in the Czech Republic: A theoretical concept or a realistic goal?
Postránecká, Z., Vejmola, Č., & Tylš, F. (2019) · Journal of Psychedelic Studies · doi:10.1556/2054.2019.003 · Cited by 7
New Insights Into the Clinical and Nonclinical Effects of Psychedelic Substances
Forstmann, M., & Sagioglou, C. (2021) · European Psychologist · doi:10.1027/1016-9040/a000447 · Cited by 7
Malpractice and Other Civil Liability in Psychedelic Psychiatry
Holoyda, B. J. (2023) · Psychiatric Services · doi:10.1176/appi.ps.20220528 · Cited by 7
Lancelotta, R., DellaCrosse, M. A., Quinn, D., Saniyah, S., Saniyah, M., Gukasyan, N., Narayan, S. K., Nikolaidis, A., Sevelius, J. M., & Davis, A. K. (2025) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2025.2520224 · Cited by 7
Erhan, E., Külahlı, İ., Kandemir, O., Cemiloglu, R., Yigitbasi, O. G., & Cüreoğlu, S. (1996) · PubMed · Cited by 7
Psychedelics and Desistance From Crime: Lessons From the Concord Prison Experiment
Neitzke‐Spruill, L. (2022) · Journal of Humanistic Psychology · doi:10.1177/00221678221136233 · Cited by 7
Barnett, B. S., Sweat, N. W., & Hendricks, P. S. (2023) · Drug Science Policy and Law · doi:10.1177/20503245231172536 · Cited by 7
Yavorsky, C., Ballard, E. D., Opler, M. G. A., Sedway, J. A., Targum, S. D., & Lenderking, W. R. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1135828 · Cited by 7
LIMITATIONS ON THE SCIENTIFIC STUDY OF DRUG‐ENABLED MYSTICAL EXPERIENCES
Jones, R. H. (2019) · Zygon® · doi:10.1111/zygo.12546 · Cited by 7
(2019) · Cambridge University Press eBooks · doi:10.1017/9781316014165 · Cited by 7
Xiao, X., Bentzley, B. S., Cole, E. J., Tischler, C., Stimpson, K. H., Duvio, D., Bishop, J. H., DeSouza, D. D., Schatzberg, A. F., Keller, C. J., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/672154 · Cited by 7
Erratum: Making psychedelics into medicines: The politics and paradoxes of medicalization
Noorani, T. N. (2021) · Journal of Psychedelic Studies · doi:10.1556/2054.2021.10000 · Cited by 7
van Mulukom, V., Patterson, R., & van Elk, M. (2020) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/fp8e3 · Cited by 7
Qiu, T. T., & Minda, J. P. (2021) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/xrbzs · Cited by 7
Ching, T. H. W., Kichuk, S. A., DePalmer, G., Pittenger, C., & Kelmendi, B. (2022) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/85s9p · Cited by 7
Ching, T. H. W., Grazioplene, R., Pittenger, C., & Kelmendi, B. (2023) · doi:10.31234/osf.io/ba42z · Cited by 6
Tolerability, assessment, and prediction of psilocybin-induced altered states of consciousness
Studerus, E. (2012) · University of Zurich · doi:10.5167/uzh-164092 · Cited by 6
Ferreira, A. E., & Reis-Pina, P. (2024) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2024.112020 · Cited by 6
Pilot study of psilocybin in patients with post-treatment lyme disease
Garcia‐Romeu, A., Naudé, G. P., Rebman, A. W., So, S., Yaffe, A., Geithner, I., Kozero, E. A., Yang, T., Soloski, M. J., & Aucott, J. N. (2026) · Scientific Reports · doi:10.1038/s41598-026-38091-9 · Cited by 6
Ramos, L., & Vicente, S. (2024) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/13803395.2024.2363343 · Cited by 6
Bruno, V., López-Canul, M., Richardson, B., Camarini, R., Marcourakis, T., & Gobbi, G. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251368361 · Cited by 6
Argento, E., Goldenberg, S. M., Deering, K., Lavalley, J., Braschel, M. C., Bingham, B., & Shannon, K. (2022) · Drug and Alcohol Dependence Reports · doi:10.1016/j.dadr.2022.100044 · Cited by 6
Development of the Japanese version of the 30‐item Mystical Experience Questionnaire
Yonezawa, K., Tani, H., Nakajima, S., & Uchida, H. (2023) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12377 · Cited by 6
McNamara, P. (2023) · Cortex · doi:10.1016/j.cortex.2023.10.015 · Cited by 6
David, J., Berkovich‐Ohana, A., & Dor‐Ziderman, Y. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06792-0 · Cited by 6
Andersen, K. A. A., Holmøy, B., Kvam, T.-M., & Johnson, M. W. (2025) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2025.05.062 · Cited by 6
Self-citationTassell-Matamua, N., & Holden, J. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-817204-9.00005-6 · Cited by 6
Commentary on Coulson & Caulkins (2012): Optimizing drug scheduling
R.Kleiman, M. A. (2012) · Addiction · doi:10.1111/j.1360-0443.2012.03814.x · Cited by 6
Can the gut-brain axis provide insight into psilocybin's therapeutic value in reducing stress?
Kit, A., Conway, K., Makarowski, S., O'Regan, G., Allen, J., Shultz, S. R., Bodnar, T. S., & Christie, B. R. (2025) · Neurobiology of Stress · doi:10.1016/j.ynstr.2025.100732 · Cited by 5
The emotional architecture of the psychedelic brain
Moujaes, F., Rieser, N. M., Belinger, L., Herdener, M., Zahid, Z., & Preller, K. H. (2025) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2025.07.006 · Cited by 5
Inducing selflessness through a numadelic virtual reality experience: a preliminary study
Vidal, J., Andreu, C. I., Wrzesien, M., Colombo, D., Wall, J., Glowacki, D. R., Hardy, J. L., & Cebolla, A. (2025) · Virtual Reality · doi:10.1007/s10055-025-01293-z · Cited by 5
Davis, A. K., Timmermann, C., Bernal, A. M. O., Lancelotta, R., Nayak, S. M., Sepeda, N. D., Nikolaidis, A., & Griffiths, R. R. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2232379 · Cited by 5
Self-citationKorman, B. A. (2023) · Drug Science Policy and Law · doi:10.1177/20503245231191400 · Cited by 5
Metadata
- Authors
- Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R.
- Affiliations
- Johns Hopkins University (US)
- Corresponding author
- Griffiths, Roland R.
- Venue
- Psychopharmacology
- Published
- 2011-06-15
- Volume
- 218
- Issue
- 4
- Pages
- 649-665
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- PMC
- PMC3308357
- OpenAlex
- W2001101493
- Semantic Scholar
- b6a466d47ff14211f273622e5d0b584d06253237
- Cited by
- 932
- References
- 38
- Citations by year
- 2026: 59 · 2025: 97 · 2024: 115 · 2023: 110 · 2022: 107 · 2021: 94 · 2020: 64 · 2019: 65 · 2018: 48 · 2017: 51 · 2016: 40 · 2015: 18 · 2014: 23 · 2013: 18 · 2012: 14
- FWCI
- 20.03
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Institute on Drug Abuse (R01DA003889, R01DA03889)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Social Sciences › Psychology › Social Psychology › Paranormal Experiences and Beliefs
- Social Sciences › Health › Religion, Spirituality, and Psychology
- Keywords
- psilocybin, dose-response relationship, fear and anxiety, long-term psychological effects, psychedelic therapy
- MeSH terms
- Adult, Affect, Attitude, Dose-Response Relationship, Drug, Double-Blind Method, Female, Follow-Up Studies, Hallucinogens, Humans, Male, Middle Aged, Psilocybin, Surveys and Questionnaires, Time Factors, Cross-Over Studies, Spirituality
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
